Brief: Homology Medicines Subject To Execution Of Deal With Q23 Bio

Q32 Bio

16/11/2023 13:01

Nov 16 (Reuters) - Homology Medicines Inc  FIXX.O :
    * HOMOLOGY MEDICINES: SUBJECT TO EXECUTION OF DEAL WITH Q23
BIO,
TERMINATED EMPLOYMENT OF ALBERT SEYMOUR, CEO & W. BRADFORD
SMITH, CFO EFFECTIVE NOV 17


Further company coverage:  FIXX.O 

 ((Reuters.Briefs@thomsonreuters.com;))